527 results on '"Spitzweg, Christine"'
Search Results
2. Correction: Dual-targeted NIS polyplexes—a theranostic strategy toward tumors with heterogeneous receptor expression
3. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
4. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study
5. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
6. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
7. Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice
8. Molekular zielgerichtete Therapien beim radiojodrefraktären differenzierten Schilddrüsenkarzinom – Update 2022
9. The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy
10. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
11. Update zur Hypothyreose
12. Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
13. Gastroenteropancreatic Neuroendocrine Tumours
14. The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study
15. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy
16. Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
17. OR14-05 Taking Advantage Of The Interleukin-6-Biology In Differentiated Thyroid Cancer To Stimulate Sodium Iodide Symporter (NIS)-mediated Iodide Uptake In Engineered Mesenchymal Stem Cells
18. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies
19. Medikamentöse Therapieoptionen beim radioiodrefraktären differenzierten Schilddrüsenkarzinom: Update 2019
20. Zufallsbefund Schilddrüsenknoten: Wie geht es nun weiter?
21. Dual-targeted NIS polyplexes—a theranostic strategy toward tumors with heterogeneous receptor expression
22. Leveraging the immune system to treat advanced thyroid cancers
23. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma
24. Erfolgreiche Weiterentwicklung multidisziplinärer Diagnostik und Therapie bei malignen Schilddrüsentumoren
25. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
26. Supplementary Data FS1 from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice
27. Supplementary Figure S2 from Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell–Mediated Sodium Iodide Symporter (NIS) Gene 131I Therapy
28. Thyroidal Angiotensin-Converting Enzyme 2 Protein Expression and Thyroid Function Tests in Patients with COVID-19: Results from a Retrospective Case Series and a Prospective Cohort Study
29. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
30. Medulläres Schilddrüsenkarzinom.
31. Schilddrüse und Schwangerschaft.
32. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
33. Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice
34. Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma
35. Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer
36. The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin
37. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial
38. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study
39. Medulläres Schilddrüsenkarzinom
40. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets
41. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board.
42. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
43. 124I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice
44. Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
45. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
46. Preoperative Imaging with [18F]-Fluorocholine PET/CT in Primary Hyperparathyroidism
47. Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum
48. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
49. ITOG 2024 Annual Meeting Summary: New Science Informing Novel Therapeutics.
50. Selective sodium iodide symporter (NIS) gene therapy of glioblastoma mediated by EGFR-targeted lipopolyplexes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.